Salud financiera de hoja de balance de Renalytix

Salud financiera controles de criterios 2/6

Renalytix tiene un patrimonio de los accionistas total de $-8.0M y una deuda total de $8.4M, lo que sitúa su ratio deuda-patrimonio en -105.2%. Sus activos y pasivos totales son $11.3M y $19.2M respectivamente.

Información clave

-84.1%

Ratio deuda-patrimonio

US$9.34m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$4.70m
Patrimonio	-US$11.11m
Total pasivo	US$19.88m
Activos totales	US$8.77m

Actualizaciones recientes sobre salud financiera

Recent updates

Renalytix: The Investment Case Is Shot

Jul 25

Renalytix AI GAAP EPS of -$0.20, revenue of $0.81M

Jun 30

Renalytix: High Growth Artificial Intelligence Play, Nearing A Possible Breakout

Apr 05

Análisis de la situación financiera

Pasivos a corto plazo: RNLX tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: RNLX tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: RNLX tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: RNLX tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: RNLX tiene suficiente cash runway para 2 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que RNLX disponga de suficiente cash runway para 2 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Renalytix

Salud financiera controles de criterios 2/6

Información clave

Actualizaciones recientes sobre salud financiera

Renalytix Receives Non-Compliance Notice From Nasdaq

Renalytix Receives Non-Compliance Notice From Nasdaq

Recent updates

Renalytix Plc Announces Chief Financial Officer Changes

Renalytix Plc Reports Impairment Loss on Property, Equipment and Other Long-Lived Assets for the Third Quarter Ended March 31, 2024

Renalytix Plc to Report Q3, 2024 Results on May 15, 2024

Renalytix plc Announces Executive Changes, Effective from April 30, 2024

Renalytix Plc has filed a Follow-on Equity Offering in the amount of $1 million.

Renalytix Plc has filed a Follow-on Equity Offering in the amount of $4 million.

Renalytix Plc, Annual General Meeting, Apr 22, 2024

Renalytix plc's KidneyIntelX Included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease

Renalytix Plc has completed a Follow-on Equity Offering in the amount of £9.360374 million.

Renalytix Plc has filed a Follow-on Equity Offering in the amount of £7.8 million.

Centers for Medicare & Medicaid Services Publishes Draft Local Coverage Determination for Renalytix Plc's Kidneyintelx and Kidneyintelx.Dkd

Renalytix plc Announces Update on Kidneyintelx.Dkd Local Coverage Determination Consideration

Renalytix Receives Non-Compliance Notice From Nasdaq

Renalytix Receives Non-Compliance Notice From Nasdaq

Renalytix plc Announces Step Down of Chirag Parikh as Independent Non-Executive Director

Renalytix Plc to Report Q1, 2024 Results on Nov 14, 2023

Renalytix Plc, Annual General Meeting, Dec 15, 2023

Renalytix Plc Announces the Stepped Down of Timothy Scannell as Independent Non-Executive Director

Renalytix Plc to Report Second Half, 2023 Results on Sep 28, 2023

Renalytix plc Announces the Appointment of Howard Doran as Chief Business Officer

Renalytix plc Announces Appointments to Its Clinical Advisory Board

Renalytix Plc Announces Late-Breaking KidneyIntelX Evidence Released at American Diabetes Association Scientific Sessions

Renalytix plc Appoints Catherine Coste to Board of Directors, Non-Executive Chair of the Audit Committee and a Member of the Remuneration Committee

Fda Grants De Novo Marketing Authorization for Kidneyintelx.Dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease of Renalytix plc

Renalytix Plc Announces KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences

New major risk - Financial position

Renalytix Plc to Report Q3, 2023 Results on Jun 09, 2023

Renalytix Plc, Annual General Meeting, Jun 08, 2023

Renalytix plc Announces the Launch of PRIME-CKD

Renalytix plc Announces That Primary Care Use of Kidneyintelx in Early Stage Ckd Improved Clinical Care Delivery and Outcomes

Renalytix Plc to Report Q1, 2023 Results on Nov 30, 2022

Renalytix Plc, Annual General Meeting, Dec 19, 2022

Renalytix Plc to Report Q4, 2022 Results on Oct 31, 2022

Renalytix plc Announces Ann Berman, Non-Executive Director and Chair of the Audit and Nomination Committees, Resigns as Director

Renalytix Plc Announces Publication of Clinical Utility Study in The AJMC

Renalytix: The Investment Case Is Shot

Renalytix AI GAAP EPS of -$0.20, revenue of $0.81M

Renalytix Plc to Report Q3, 2022 Results on Jun 30, 2022

Renalytix Plc Announces 1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients

Renalytix Helds Two Data Presentations on Kidneyintelx at American Diabetes Association 82nd Scientific Sessions

Renalytix: High Growth Artificial Intelligence Play, Nearing A Possible Breakout

Renalytix Plc announced that it expects to receive $21.2 million in funding from Heights Capital Ireland, Llc

Renalytix plc Reaches Enrollment Milestone for Building Kidneyintelx as Premier Precision Medicine Platform for Kidney Disease and Diabetes

Renalytix plc Announces the Launch of Its New Provider Access Portal, myIntelX

Renalytix plc Announces the Presentation of New Clinical Data for KidneyIntelX Bioprognostictm Testing At the World Congress of Nephrology Annual Meeting

Renalytix Announces Positive Study Results Published for KidneyIntelX™ in Monitoring Patient Response to New Drug Therapy

Renalytix: Laying The Foundations For Growth

Renalytix: Building Out A Capability To Ramp Revenue

Renalytix plc Announces Scaled-Up Implementation of the KidneyIntelX

Renalytix plc Announces Publication of Results from an External Chronic Kidney Disease Budget Impact Analysis

Renalytix AI EPS beats by $0.06, misses on revenue

Renalytix AI plc Announces Results from New Utility Study that Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care

Renalytix AI plc and the University of Utah Announce Partnership

Renalytix AI plc to Report First Half, 2021 Results on Mar 02, 2021

Centers for Medicaid & Medicare establishes MICT pathway

Renalytix AI plc Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics

Exact and Exact Sciences trade higher; Seen as beneficiaries from new CMS rule

Renalytix AI plc and DaVita Announce Partnership

Nkf and Renalytixai Partner to Improve Management of Early Stage Kidney Disease

Renalytix AI EPS misses by $0.04

Renalytix AI plc, Annual General Meeting, Dec 07, 2020

Kantaro Biosciences, LLC, Joint Venture Between Mount Sinai Health System and RenalytixAI, and Partner Bio-Techne Corporation Receive CE Marking for COVID-SeroKlir and COVID-SeroIndex

Renalytix AI plc to Report Fiscal Year 2020 Results on Oct 27, 2020

Renalytix AI, Inc. Receives California Clinical Laboratory License from the California Department of Health for Its Clinical Laboratory in Salt Lake City, Utah

Renalytix AI plc Announces the Commercial Launch of the KidneyIntelX Clinical Test Reporting Platform

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera